Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics (HOWL) will merge with Ambros Therapeutics in an all-stock deal, with a $150M private placement. The combined company, Ambros Therapeutics, will trade as AMBX and focus on CRPS-1 treatments. The deal is expected to close by Q1 2027, pending approvals.

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal, with the combined company focusing on Ambros's neridronate program. The deal includes a $150M private placement. Post-merger, Ambros will operate as AMBX on Nasdaq, led by its current team. Werewolf shares rose 125% pre-market to $0.95.

Andersen Group Inc. announced a secondary offering of 4.28 million shares of Class A common stock at $44 per share, with gross proceeds of $188.5 million for selling stockholders. The offering is expected to close on August 21, 2026, with underwriters having a 30-day option to purchase additional shares. Andersen is not selling shares and will not receive proceeds. Latham & Watkins LLP represents the underwriters.